FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130853875> ?p ?o ?g. }

• W2130853875 endingPage "0" @default.
• W2130853875 startingPage "1367" @default.
• W2130853875 abstract "<h3>Abstract</h3> <b>Objective</b> To explore the efficacy and safety of fluticasone propionate, cream and ointment, applied twice weekly in addition to maintenance treatment with emollients, in reducing the risk of relapse of chronic recurrent atopic dermatitis. <b>Design</b> Randomised, double blind, parallel group study of 20 weeks9 duration. <b>Setting</b> Dermatology outpatient clinics (6 countries, 39 centres). <b>Participants</b> Adult (aged 12-65) patients with moderate to severe atopic dermatitis who were experiencing a flare. <b>Methods</b> Participants applied fluticasone propionate (0.05% cream or 0.005% ointment; once or twice daily) regularly for four weeks to stabilise their condition. The patients whose disease was brought under control then continued into a 16 week maintenance phase, applying emollient on a daily basis with a bath oil as needed and either the same formulation of fluticasone propionate or its placebo base (emollient alone) twice weekly to the areas that were usually affected. <b>Main outcome measure</b> Time to relapse of atopic dermatitis during maintenance phase. <b>Results</b> 376 patients entered the stabilisation phase, and 295 continued into the maintenance phase. After 16 weeks in the maintenance phase, the disease remained under control in 133 patients (87 using fluticasone propionate twice weekly, 46 using emollient alone), 135 (40 fluticasone propionate, 95 emollient) had experienced a relapse, and 27 had discontinued. Median time to relapse was six weeks for emollient alone compared with more than 16 weeks for additional fluticasone propionate. Patients who applied fluticasone propionate cream twice weekly were 5.8 times less likely (95% confidence interval 3.1 to 10.8, P < 0.001) and patients using fluticasone propionate ointment 1.9 times less likely (1.2 to 3.2, P=0.010) to have a relapse than patients applying emollient alone. The groups showed no differences in adverse events. <b>Conclusion</b> After atopic dermatitis had been stabilised the addition of fluticasone propionate twice weekly to maintenance treatment with emollients significantly reduced the risk of relapse." @default.
• W2130853875 created "2016-06-24" @default.
• W2130853875 creator A5012828960 @default.
• W2130853875 creator A5014281585 @default.
• W2130853875 creator A5038182570 @default.
• W2130853875 creator A5044160994 @default.
• W2130853875 creator A5049852887 @default.
• W2130853875 creator A5055354744 @default.
• W2130853875 creator A5057014318 @default.
• W2130853875 date "2003-06-19" @default.
• W2130853875 modified "2023-10-12" @default.
• W2130853875 title "Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study" @default.
• W2130853875 cites W1968743461 @default.
• W2130853875 cites W1982906465 @default.
• W2130853875 cites W2004418540 @default.
• W2130853875 cites W2039623610 @default.
• W2130853875 cites W2054759068 @default.
• W2130853875 cites W2074243567 @default.
• W2130853875 cites W2100877179 @default.
• W2130853875 cites W2102780769 @default.
• W2130853875 cites W2106200506 @default.
• W2130853875 cites W2117904112 @default.
• W2130853875 cites W2120168287 @default.
• W2130853875 cites W2141110046 @default.
• W2130853875 cites W2165254830 @default.
• W2130853875 cites W4319293042 @default.
• W2130853875 doi "https://doi.org/10.1136/bmj.326.7403.1367" @default.
• W2130853875 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/162129" @default.
• W2130853875 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12816824" @default.
• W2130853875 hasPublicationYear "2003" @default.
• W2130853875 type Work @default.
• W2130853875 sameAs 2130853875 @default.
• W2130853875 citedByCount "284" @default.
• W2130853875 countsByYear W21308538752012 @default.
• W2130853875 countsByYear W21308538752013 @default.
• W2130853875 countsByYear W21308538752014 @default.
• W2130853875 countsByYear W21308538752015 @default.
• W2130853875 countsByYear W21308538752016 @default.
• W2130853875 countsByYear W21308538752017 @default.
• W2130853875 countsByYear W21308538752018 @default.
• W2130853875 countsByYear W21308538752019 @default.
• W2130853875 countsByYear W21308538752020 @default.
• W2130853875 countsByYear W21308538752021 @default.
• W2130853875 countsByYear W21308538752022 @default.
• W2130853875 countsByYear W21308538752023 @default.
• W2130853875 crossrefType "journal-article" @default.
• W2130853875 hasAuthorship W2130853875A5012828960 @default.
• W2130853875 hasAuthorship W2130853875A5014281585 @default.
• W2130853875 hasAuthorship W2130853875A5038182570 @default.
• W2130853875 hasAuthorship W2130853875A5044160994 @default.
• W2130853875 hasAuthorship W2130853875A5049852887 @default.
• W2130853875 hasAuthorship W2130853875A5055354744 @default.
• W2130853875 hasAuthorship W2130853875A5057014318 @default.
• W2130853875 hasBestOaLocation W21308538752 @default.
• W2130853875 hasConcept C126322002 @default.
• W2130853875 hasConcept C142724271 @default.
• W2130853875 hasConcept C16005928 @default.
• W2130853875 hasConcept C204787440 @default.
• W2130853875 hasConcept C27081682 @default.
• W2130853875 hasConcept C2776804153 @default.
• W2130853875 hasConcept C2777785397 @default.
• W2130853875 hasConcept C2778329239 @default.
• W2130853875 hasConcept C2779028295 @default.
• W2130853875 hasConcept C2781212218 @default.
• W2130853875 hasConcept C71924100 @default.
• W2130853875 hasConcept C90924648 @default.
• W2130853875 hasConceptScore W2130853875C126322002 @default.
• W2130853875 hasConceptScore W2130853875C142724271 @default.
• W2130853875 hasConceptScore W2130853875C16005928 @default.
• W2130853875 hasConceptScore W2130853875C204787440 @default.
• W2130853875 hasConceptScore W2130853875C27081682 @default.
• W2130853875 hasConceptScore W2130853875C2776804153 @default.
• W2130853875 hasConceptScore W2130853875C2777785397 @default.
• W2130853875 hasConceptScore W2130853875C2778329239 @default.
• W2130853875 hasConceptScore W2130853875C2779028295 @default.
• W2130853875 hasConceptScore W2130853875C2781212218 @default.
• W2130853875 hasConceptScore W2130853875C71924100 @default.
• W2130853875 hasConceptScore W2130853875C90924648 @default.
• W2130853875 hasIssue "7403" @default.
• W2130853875 hasLocation W21308538751 @default.
• W2130853875 hasLocation W21308538752 @default.
• W2130853875 hasLocation W21308538753 @default.
• W2130853875 hasLocation W21308538754 @default.
• W2130853875 hasOpenAccess W2130853875 @default.
• W2130853875 hasPrimaryLocation W21308538751 @default.
• W2130853875 hasRelatedWork W1975221239 @default.
• W2130853875 hasRelatedWork W1992988294 @default.
• W2130853875 hasRelatedWork W2020812663 @default.
• W2130853875 hasRelatedWork W2030829101 @default.
• W2130853875 hasRelatedWork W2040008754 @default.
• W2130853875 hasRelatedWork W2055935555 @default.
• W2130853875 hasRelatedWork W2160477136 @default.
• W2130853875 hasRelatedWork W2343833591 @default.
• W2130853875 hasRelatedWork W3030704863 @default.
• W2130853875 hasRelatedWork W4231997767 @default.
• W2130853875 hasVolume "326" @default.
• W2130853875 isParatext "false" @default.
• W2130853875 isRetracted "false" @default.

• next